Email ID
Sign me in automatically next time
Published trial adds weight to Takeda's confidence in next-generation antidiabetic

The first full results to be published from a Phase II trial with Takeda's first-in-class oral antidiabetic TAK-875 confirm both efficacy benefits for the GPR40 agonist and a significantly lower...
27 February 2012
Ian Haydock

Please Login to read the full article.
04 April 2016
Stockholm, Sweden
06 April 2016
Hamburg, Germany
JOB OF THE WEEK Promote your job vacancy
© 2016 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36